Publications by authors named "M Akova"
Article Synopsis
- - The study examines the use of antimicrobial prophylaxis (AMP) in haematological patients, particularly those at high risk for bacterial infections due to prolonged neutropenia after chemotherapy, amidst the rise of multi-drug resistant Gram-negative bacteria (MDR-GNB).
- - A survey conducted with 120 haematology centers across 28 European countries revealed that most centers (86.7%) routinely screen for MDR-GNB, with a significant number (39.2%) using fluoroquinolones for prophylaxis.
- - While bloodstream infections (BSI) rates were slightly lower in patients receiving AMP, the overall increase in MDR-GNB infections highlights the need for improved antimicrobial stewardship and tailored prophylactic strategies.
Objectives: COVID-19 unravelled new ethical issues in the neglected field of infectious diseases ethics (IDE). We investigated IDE involvement among infectious diseases professionals.
Methods: A global survey was disseminated during 2021-2022.
Although occult fungal, viral, and multidrug-resistant bacterial infections can cause persistent fever in neutropenic patients with hematologic cancer, a variety of noninfectious entities should be considered on a case-by-case basis in the context of negative diagnostic workup for infection.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted on 227 febrile neutropenia (FN) patients to assess how a local guideline and a computerized decision support system (CDSS) affected the quality of treatment from April 2016 to January 2019.
- The results showed a significant increase in appropriate empirical antibacterial treatment from 58.3% to 88.1% after the guideline's implementation, along with a reduced need for treatment escalation (49.5% to 35.3%).
- Furthermore, the CDSS performed similarly to consulting physicians in recommending appropriate treatment, indicating its effectiveness in aligning with local treatment protocols.
Background: There has been an unprecedented increase in the number of immunocompromised (IC) patients in clinical practice due to various reasons. Bacterial infections are a major cause of morbidity and mortality in this population. Emerging antibacterial resistance poses a significant challenge for prophylaxis and treatment.
View Article and Find Full Text PDF